QualityStocks News - Zenosense, Inc. (ZENO) Co-Develops a Super-Bug Detector

QualityStocks would like to highlight Zenosense (OTCQB: ZENO). The company is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.

In the company’s news,

Zenosense is focused on emerging healthcare technology, specifically, on a device that detects Methicillin-resistant Staphylococcus aureus (MRSA) in hospitals and other healthcare settings.

Founded in 2008, Zenosense was previously known as Braeden Valley Mines and adopted its present name in November of 2013. From the start, the company’s sole aim has been to co-develop an operational MRSA detector (by way of licensed technology) that could be sold to healthcare providers for use in clinical environments.

Zenosense believes there is a huge underlying demand for a cost-effective MRSA detector and that it has identified a lucrative new market segment for a wearable detection device. The costs of MRSA and other hospital-acquired infections to both patients and healthcare providers amount to tens of thousands of invasive infections and deaths as well as billions of dollars in treatments costs, and have spurred Zenosense’s MRSA detection device initiative.

Over the years, MRSA has placed a high financial toll on private and public health care systems, creating a critical issue for healthcare providers and authorities. Early detection of the bug is imperative so that protective actions, such as deep cleaning and ward/patient isolation, can be performed.

Zenosense has an outsourced development model; it has contracted out the development of the device to the Sgenia Group, a known sensor developer with the ability to produce such a sophisticated device. The development of the device started in December 2013 and, should Zenosense successfully co-develop a cost-effective MRSA detector to address the multibillion dollar, and often lethal, MRSA problem, it will likely be extremely attractive to potential distribution partners and end users.

To develop the MRSA device for Zenosense, Sgenia has set up a dedicated subsidiary, Zenon Biosystem. Sgenia already supplies the sensors used in the Tokamak device for important, global nuclear fusion research project. The company also produces an algal contamination detector for use in water supply applications. This detector speedily and successfully scans for unstable organic compounds released by the target algae; a distinctive “chemical signature” that ascertains the presence or absence of the algae. The Sgenia detector is effectively an electronic “nose” that can smell this signature, and Zenon will be using essential elements of this technology platform to develop the MRSA device for Zenosense.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net  

To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage

To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks

Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net   

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.